Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1921

1.

Successful use of flexible silicone mesh for management of prolonged open abdomen.

Tsutsumi R, Akahoshi T, Ikeda T, Maehara Y, Hashizume M.

Acute Med Surg. 2019 Aug 1;6(4):400-403. doi: 10.1002/ams2.438. eCollection 2019 Oct.

2.

Risk factors for the metabolic syndrome components of hypertension, diabetes mellitus, and dyslipidemia after living donor liver transplantation.

Toshima T, Yoshizumi T, Inokuchi S, Kosai-Fujimoto Y, Kurihara T, Yoshiya S, Mano Y, Takeishi K, Itoh S, Harada N, Ikegami T, Soejima Y, Shimokawa M, Maehara Y, Mori M.

HPB (Oxford). 2019 Sep 24. pii: S1365-182X(19)30695-1. doi: 10.1016/j.hpb.2019.08.008. [Epub ahead of print]

PMID:
31561946
3.

JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer.

Yoshino T, Kotaka M, Shinozaki K, Touyama T, Manaka D, Matsui T, Ishigure K, Hasegawa J, Inoue K, Munemoto Y, Takagane A, Ishikawa H, Ishida H, Ogata Y, Oba K, Goto K, Sakamoto J, Maehara Y, Ohtsu A.

Cancer Chemother Pharmacol. 2019 Sep 23. doi: 10.1007/s00280-019-03957-5. [Epub ahead of print]

PMID:
31549217
4.

The evolution of surgical treatment for gastrointestinal cancers.

Maehara Y, Soejima Y, Yoshizumi T, Kawahara N, Oki E, Saeki H, Akahoshi T, Ikegami T, Yamashita YI, Furuyama T, Sugimachi K, Harada N, Tagawa T, Harimoto N, Itoh S, Sonoda H, Ando K, Nakashima Y, Nagao Y, Yamashita N, Kasagi Y, Yukaya T, Kurihara T, Tsutsumi R, Takamori S, Sasaki S, Ikeda T, Yonemitsu Y, Fukuhara T, Kitao H, Iimori M, Kataoka Y, Wakasa T, Suzuki M, Teraishi K, Yoshida Y, Mori M.

Int J Clin Oncol. 2019 Nov;24(11):1333-1349. doi: 10.1007/s10147-019-01499-7. Epub 2019 Sep 14.

PMID:
31522313
5.

Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial.

Yoshino T, Yamanaka T, Oki E, Kotaka M, Manaka D, Eto T, Hasegawa J, Takagane A, Nakamura M, Kato T, Munemoto Y, Takeuchi S, Bando H, Taniguchi H, Gamoh M, Shiozawa M, Mizushima T, Saji S, Maehara Y, Ohtsu A, Mori M.

JAMA Oncol. 2019 Sep 12. doi: 10.1001/jamaoncol.2019.2572. [Epub ahead of print]

PMID:
31513248
6.

Prognostic significance of inflammatory biomarkers in hepatocellular carcinoma following hepatic resection.

Itoh S, Yugawa K, Shimokawa M, Yoshiya S, Mano Y, Takeishi K, Toshima T, Maehara Y, Mori M, Yoshizumi T.

BJS Open. 2019 Apr 29;3(4):500-508. doi: 10.1002/bjs5.50170. eCollection 2019 Aug.

7.

ASO Author Reflections: PD-L2 Expression in Lung Squamous Cell Carcinoma-One of the Potential Important Prognostic Factors.

Matsubara T, Takada K, Maehara Y.

Ann Surg Oncol. 2019 Aug 5. doi: 10.1245/s10434-019-07684-2. [Epub ahead of print] No abstract available.

PMID:
31385129
8.
9.

Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial).

Oki E, Emi Y, Yamanaka T, Uetake H, Muro K, Takahashi T, Nagasaka T, Hatano E, Ojima H, Manaka D, Kusumoto T, Katayose Y, Fujiwara T, Yoshida K, Unno M, Hyodo I, Tomita N, Sugihara K, Maehara Y.

Br J Cancer. 2019 Jul;121(3):222-229. doi: 10.1038/s41416-019-0518-2. Epub 2019 Jul 9.

10.

Principles and development of collagen-mediated tissue fusion induced by laser irradiation.

Sasaki S, Ikeda T, Okihara SI, Nishimura S, Nakadate R, Saeki H, Oki E, Mori M, Hashizume M, Maehara Y.

Sci Rep. 2019 Jun 28;9(1):9383. doi: 10.1038/s41598-019-45486-4.

11.

Tracheal Size and Morphology on the Reconstructed CT Imaging.

Mizuguchi S, Motomura Y, Maki J, Baba R, Ichimiya Y, Tokuda K, Kaku N, Takada H, Maehara Y, Ohga S.

Pediatr Crit Care Med. 2019 Aug;20(8):e366-e371. doi: 10.1097/PCC.0000000000001996.

PMID:
31162371
12.

Cytotoxicity of trifluridine correlates with the thymidine kinase 1 expression level.

Kataoka Y, Iimori M, Niimi S, Tsukihara H, Wakasa T, Saeki H, Oki E, Maehara Y, Kitao H.

Sci Rep. 2019 May 28;9(1):7964. doi: 10.1038/s41598-019-44399-6.

13.

Late-onset sepsis and encephalopathy after bicycle-spoke injury: a case report.

Takemoto R, Motomura Y, Kaku N, Ichimiya Y, Muraoka M, Kanno S, Tanaka T, Sakai Y, Maehara Y, Ohga S.

BMC Infect Dis. 2019 May 28;19(1):472. doi: 10.1186/s12879-019-4082-4.

14.

Prognosis of Early-stage Part-solid and Pure-solid Lung Adenocarcinomas.

Kinoshita F, Toyokawa G, Matsubara T, Kozuma Y, Haratake N, Takamori S, Akamine T, Hirai F, Takenaka T, Tagawa T, Maehara Y.

Anticancer Res. 2019 May;39(5):2665-2670. doi: 10.21873/anticanres.13391.

PMID:
31092466
15.

Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A).

Sasaki S, Oki E, Saeki H, Shimose T, Sakamoto S, Hu Q, Kudo K, Tsuda Y, Nakashima Y, Ando K, Akagi Y, Kakeji Y, Baba H, Maehara Y.

Int J Clin Oncol. 2019 Oct;24(10):1204-1213. doi: 10.1007/s10147-019-01460-8. Epub 2019 May 6.

PMID:
31062115
16.

Efficacy of Novel Multispectral Imaging Device to Determine Anastomosis for Esophagogastrostomy.

Tsutsumi R, Ikeda T, Nagahara H, Saeki H, Nakashima Y, Oki E, Maehara Y, Hashizume M.

J Surg Res. 2019 Oct;242:11-22. doi: 10.1016/j.jss.2019.04.033. Epub 2019 May 3.

17.

A novel prognostic marker in patients with non-small cell lung cancer: musculo-immuno-nutritional score calculated by controlling nutritional status and creatine kinase.

Takamori S, Toyokawa G, Shimokawa M, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Hirai F, Tagawa T, Oda Y, Maehara Y.

J Thorac Dis. 2019 Mar;11(3):927-935. doi: 10.21037/jtd.2019.01.76.

18.

Bone morphogenetic protein 4 provides cancer-supportive phenotypes to liver fibroblasts in patients with hepatocellular carcinoma.

Mano Y, Yoshio S, Shoji H, Tomonari S, Aoki Y, Aoyanagi N, Okamoto T, Matsuura Y, Osawa Y, Kimura K, Yugawa K, Wang H, Oda Y, Yoshizumi T, Maehara Y, Kanto T.

J Gastroenterol. 2019 Apr 2. doi: 10.1007/s00535-019-01579-5. [Epub ahead of print]

PMID:
30941514
19.

IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer.

Imai D, Yoshizumi T, Okano S, Itoh S, Ikegami T, Harada N, Aishima S, Oda Y, Maehara Y.

J Surg Res. 2019 Aug;240:115-123. doi: 10.1016/j.jss.2019.02.038. Epub 2019 Mar 27.

PMID:
30927618
20.

[A Study of the Usefulness of Decompression in Treating Bowel Obstruction Due to Colorectal Cancer].

Higashi T, Ikeda Y, Nobutou Y, Ohgaki K, Kinjou N, Maehara S, Nakamura T, Teramoto S, Saito G, Adachi E, Kounoe S, Maehara Y.

Gan To Kagaku Ryoho. 2019 Feb;46(2):318-320. Japanese.

PMID:
30914546
21.

External validation of CLI Frailty Index and assessment of predictive value of modified CLI Frailty Index for patients with critical limb ischemia undergoing infrainguinal revascularization.

Morisaki K, Furuyama T, Matsubara Y, Inoue K, Kurose S, Yoshino S, Nakayama K, Yamashita S, Yoshiya K, Yoshiga R, Maehara Y.

Vascular. 2019 Aug;27(4):405-410. doi: 10.1177/1708538119836005. Epub 2019 Mar 19. No abstract available.

PMID:
30890090
22.

Tumor suppressor KIF1Bβ regulates mitochondrial apoptosis in collaboration with YME1L1.

Ando K, Yokochi T, Mukai A, Wei G, Li Y, Kramer S, Ozaki T, Maehara Y, Nakagawara A.

Mol Carcinog. 2019 Jul;58(7):1134-1144. doi: 10.1002/mc.22997. Epub 2019 Mar 11.

23.

Short- and Long-term Outcomes of Surgical Treatment for Remnant Gastric Cancer After Distal Gastrectomy.

Nakaji YU, Saeki H, Kudou K, Nakanishi R, Sugiyama M, Nakashima Y, Ando K, Oda Y, Oki E, Maehara Y.

Anticancer Res. 2019 Mar;39(3):1411-1415. doi: 10.21873/anticanres.13256.

PMID:
30842176
24.

Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study.

Tomita N, Kunieda K, Maeda A, Hamada C, Yamanaka T, Sato T, Yoshida K, Boku N, Nezu R, Yamaguchi S, Mishima H, Sadahiro S, Muro K, Ishiguro M, Sakamoto J, Saji S, Maehara Y.

Br J Cancer. 2019 Apr;120(7):689-696. doi: 10.1038/s41416-019-0410-0. Epub 2019 Mar 5.

25.

A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma.

Matsubara T, Takada K, Azuma K, Takamori S, Toyokawa G, Haro A, Osoegawa A, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.

Ann Surg Oncol. 2019 Jun;26(6):1925-1933. doi: 10.1245/s10434-019-07257-3. Epub 2019 Feb 27.

PMID:
30815803
26.

Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients.

Takamori S, Takada K, Azuma K, Jogo T, Shimokawa M, Toyokawa G, Hirai F, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.

Ann Surg Oncol. 2019 Jun;26(6):1916-1924. doi: 10.1245/s10434-019-07231-z. Epub 2019 Feb 27.

PMID:
30815801
27.

Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience.

Ueda Y, Kobayashi T, Ikegami T, Miuma S, Mizuno S, Akamatsu N, Takaki A, Ishigami M, Takatsuki M, Sugawara Y, Maehara Y, Uemoto S, Seno H.

J Gastroenterol. 2019 Jul;54(7):660-666. doi: 10.1007/s00535-019-01561-1. Epub 2019 Feb 26.

PMID:
30806783
28.

Daikenchuto accelerates the recovery from prolonged postoperative ileus after open abdominal surgery: a subgroup analysis of three randomized controlled trials.

Kono T, Shimada M, Nishi M, Morine Y, Yoshikawa K, Katsuno H, Maeda K, Koeda K, Morita S, Watanabe M, Kusano M, Sakamoto J, Saji S, Sokuoka H, Sato Y, Maehara Y, Kanematsu T, Kitajima M.

Surg Today. 2019 Aug;49(8):704-711. doi: 10.1007/s00595-019-01787-9. Epub 2019 Feb 25.

29.

The Significance of CD44 Variant 9 in Resected Lung Adenocarcinoma: Correlation with Pathological Early-Stage and EGFR Mutation.

Akamine T, Tagawa T, Ijichi K, Toyokawa G, Takamori S, Hirai F, Okamoto T, Oda Y, Maehara Y.

Ann Surg Oncol. 2019 May;26(5):1544-1551. doi: 10.1245/s10434-018-07137-2. Epub 2019 Feb 24.

PMID:
30798450
30.

Successful Bridge Therapy with Initial Endovascular Repair for Arterioenteric Fistula Resulting from Pseudoaneurysm Rupture with Massive Gastrointestinal Hemorrhage after Pancreas Transplantation.

Kurose S, Inoue K, Yoshino S, Nakayama K, Yamashita S, Yoshiya K, Yoshiga R, Morisaki K, Kaku K, Okabe Y, Furuyama T, Maehara Y.

Ann Vasc Surg. 2019 Jul;58:379.e15-379.e22. doi: 10.1016/j.avsg.2018.10.028. Epub 2019 Jan 31.

PMID:
30711503
31.

Y-box binding protein YBX1 and its correlated genes as biomarkers for poor outcomes in patients with breast cancer.

Shibata T, Tokunaga E, Hattori S, Watari K, Murakami Y, Yamashita N, Oki E, Itou J, Toi M, Maehara Y, Kuwano M, Ono M.

Oncotarget. 2018 Dec 14;9(98):37216-37228. doi: 10.18632/oncotarget.26469. eCollection 2018 Dec 14.

32.

POGLUT1, the putative effector gene driven by rs2293370 in primary biliary cholangitis susceptibility locus chromosome 3q13.33.

Hitomi Y, Ueno K, Kawai Y, Nishida N, Kojima K, Kawashima M, Aiba Y, Nakamura H, Kouno H, Kouno H, Ohta H, Sugi K, Nikami T, Yamashita T, Katsushima S, Komeda T, Ario K, Naganuma A, Shimada M, Hirashima N, Yoshizawa K, Makita F, Furuta K, Kikuchi M, Naeshiro N, Takahashi H, Mano Y, Yamashita H, Matsushita K, Tsunematsu S, Yabuuchi I, Nishimura H, Shimada Y, Yamauchi K, Komatsu T, Sugimoto R, Sakai H, Mita E, Koda M, Nakamura Y, Kamitsukasa H, Sato T, Nakamuta M, Masaki N, Takikawa H, Tanaka A, Ohira H, Zeniya M, Abe M, Kaneko S, Honda M, Arai K, Arinaga-Hino T, Hashimoto E, Taniai M, Umemura T, Joshita S, Nakao K, Ichikawa T, Shibata H, Takaki A, Yamagiwa S, Seike M, Sakisaka S, Takeyama Y, Harada M, Senju M, Yokosuka O, Kanda T, Ueno Y, Ebinuma H, Himoto T, Murata K, Shimoda S, Nagaoka S, Abiru S, Komori A, Migita K, Ito M, Yatsuhashi H, Maehara Y, Uemoto S, Kokudo N, Nagasaki M, Tokunaga K, Nakamura M.

Sci Rep. 2019 Jan 14;9(1):102. doi: 10.1038/s41598-018-36490-1.

33.

Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy.

Takada K, Kohashi K, Shimokawa M, Haro A, Osoegawa A, Tagawa T, Seto T, Oda Y, Maehara Y.

Lung Cancer. 2019 Feb;128:26-32. doi: 10.1016/j.lungcan.2018.12.008. Epub 2018 Dec 10.

PMID:
30642449
34.

Primary amelanotic malignant melanoma of the esophagus: a case report.

Koga N, Kubo N, Saeki H, Sasaki S, Jogo T, Hirose K, Nakashima Y, Oki E, Koga Y, Oda Y, Oiwa H, Oiwa T, Maehara Y.

Surg Case Rep. 2019 Jan 11;5(1):4. doi: 10.1186/s40792-019-0564-2.

35.

The prognostic impact of obstructive lung disease on survival of never smokers with resected non-small-cell lung cancer: a comparison with smokers.

Akamine T, Tagawa T, Shimokawa M, Matsubara T, Kozuma Y, Haratake N, Takamori S, Toyokawa G, Maehara Y.

Interact Cardiovasc Thorac Surg. 2019 May 1;28(5):735-743. doi: 10.1093/icvts/ivy329.

PMID:
30602039
36.

Functional Analysis of Human Hepatocytes Isolated From Chimeric Mouse Liver.

Harimoto N, Nakagawara H, Shirabe K, Yoshizumi T, Itoh S, Ikegami T, Soejima Y, Maehara Y, Ishida Y, Tateno C, Tanaka Y.

Transplant Proc. 2018 Dec;50(10):3858-3862. doi: 10.1016/j.transproceed.2018.06.035. Epub 2018 Jun 30.

PMID:
30577278
37.

Real-Time Ultrasound-Guided Thrombectomy for Extensive Portal Vein Thrombosis in Living Donor Liver Transplantation.

Soejima Y, Yoshizumi T, Ikegami T, Harimoto N, Harada N, Itoh S, Toshima T, Motomura T, Mano Y, Ohira M, Bekki Y, Maehara Y.

Transplant Proc. 2018 Dec;50(10):3549-3551. doi: 10.1016/j.transproceed.2018.08.047. Epub 2018 Sep 6.

PMID:
30577235
38.

HMGB1 blockade significantly improves luminal fibrous obliteration in a murine model of bronchiolitis obliterans syndrome.

Takamori S, Shoji F, Okamoto T, Kozuma Y, Matsubara T, Haratake N, Akamine T, Katsura M, Takada K, Toyokawa G, Tagawa T, Maehara Y.

Transpl Immunol. 2019 Apr;53:13-20. doi: 10.1016/j.trim.2018.11.007. Epub 2018 Dec 1.

PMID:
30508580
39.

Neoadjuvant Chemotherapy Versus Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma.

Nakashima Y, Saeki H, Hu Q, Tsuda Y, Hisamatsu Y, Ando K, Oki E, Maehara Y.

Anticancer Res. 2018 Dec;38(12):6809-6814. doi: 10.21873/anticanres.13053.

PMID:
30504394
40.

Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical Cancer.

Hashimoto D, Arima K, Nakagawa S, Negoro Y, Hirata T, Hirota M, Inomata M, Fukuzawa K, Ohga T, Saeki H, Oki E, Yamashita YI, Chikamoto A, Baba H, Maehara Y.

J Gastroenterol. 2019 May;54(5):437-448. doi: 10.1007/s00535-018-01535-9. Epub 2018 Dec 4.

PMID:
30515563
41.

Postoperative Skeletal Muscle Loss Predicts Poor Prognosis of Adenocarcinoma of Upper Stomach and Esophagogastric Junction.

Kudou K, Saeki H, Nakashima Y, Kimura K, Ando K, Oki E, Ikeda T, Maehara Y.

World J Surg. 2019 Apr;43(4):1068-1075. doi: 10.1007/s00268-018-4873-6.

PMID:
30478682
42.

CD44v9 is associated with epithelial-mesenchymal transition and poor outcomes in esophageal squamous cell carcinoma.

Taniguchi D, Saeki H, Nakashima Y, Kudou K, Nakanishi R, Kubo N, Ando K, Oki E, Oda Y, Maehara Y.

Cancer Med. 2018 Dec;7(12):6258-6268. doi: 10.1002/cam4.1874. Epub 2018 Nov 26.

43.

Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors.

Takamori S, Takada K, Tagawa T, Toyokawa G, Hirai F, Yamashita N, Okamoto T, Oki E, Yoshizumi T, Oda Y, Maehara Y.

Surg Oncol. 2018 Dec;27(4):637-641. doi: 10.1016/j.suronc.2018.08.001. Epub 2018 Aug 11.

PMID:
30449485
44.

Impact of Osteopenia in Liver Cirrhosis: Special Reference to Standard Bone Mineral Density with Age.

Toshima T, Yoshizumi T, Ikegami T, Harada N, Itoh S, Mano Y, Motomura T, Soejima Y, Maehara Y.

Anticancer Res. 2018 Nov;38(11):6465-6471. doi: 10.21873/anticanres.13009.

PMID:
30396973
45.

BUBR1 Insufficiency Is Correlated with eNOS Reduction Experimentally In Vitro and In Vivo, and in Gastric Cancer Tissue.

Kawakubo E, Matsumoto T, Yoshiya K, Yamashita S, Jogo T, Saeki H, Oki E, Furuyama T, Oda Y, Maehara Y.

Anticancer Res. 2018 Nov;38(11):6099-6106. doi: 10.21873/anticanres.12960.

PMID:
30396924
46.

Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).

Saeki H, Oki E, Kashiwada T, Arigami T, Makiyama A, Iwatsuki M, Narita Y, Satake H, Matsuda Y, Sonoda H, Shimokawa M, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC).

Eur J Cancer. 2018 Dec;105:41-49. doi: 10.1016/j.ejca.2018.09.024. Epub 2018 Nov 2.

PMID:
30391779
47.

Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study.

Takada K, Toyokawa G, Azuma K, Takamori S, Jogo T, Hirai F, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.

In Vivo. 2018 Nov-Dec;32(6):1541-1550. doi: 10.21873/invivo.11412.

48.

Changes in HER2 Expression and Amplification Status Following Preoperative Chemotherapy for Gastric Cancer.

Shu S, Iimori M, Nakanishi R, Jogo T, Saeki H, Oki E, Maehara Y.

In Vivo. 2018 Nov-Dec;32(6):1491-1498. doi: 10.21873/invivo.11405.

49.

A Positive Correlation Between the EZH2 and PD-L1 Expression in Resected Lung Adenocarcinomas.

Toyokawa G, Takada K, Tagawa T, Hamamoto R, Yamada Y, Shimokawa M, Oda Y, Maehara Y.

Ann Thorac Surg. 2019 Feb;107(2):393-400. doi: 10.1016/j.athoracsur.2018.08.056. Epub 2018 Oct 18.

PMID:
30343006
50.

Effect of lateral lymph node dissection for mid and low rectal cancer: An ad-hoc analysis of the ACTS-RC (JFMC35-C1) randomized clinical trial.

Oki E, Shimokawa M, Ando K, Murata A, Takahashi T, Maeda K, Kusumoto T, Munemoto Y, Nakanishi R, Nakashima Y, Saeki H, Maehara Y.

Surgery. 2019 Mar;165(3):586-592. doi: 10.1016/j.surg.2018.08.027. Epub 2018 Oct 9.

PMID:
30314724

Supplemental Content

Loading ...
Support Center